InMode (INMD) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neuraxis (NRXS) has outperformed InMode (INMD) over the past year, gaining 61.1% versus a loss of 11.7%. InMode is the larger company by market cap ($714.7 million vs $59.9 million), about 11.9 times the size, while Neuraxis is growing revenue faster (+32.9% vs -6.2%). InMode converts more of its revenue into profit, with a net margin of 25.3% versus -218.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INMD | NRXS |
|---|---|---|
| Share price | $12.42 | $4.22 |
| Market cap | $714.70M | $59.90M |
| 1-day change | -2.20% | -6.22% |
| YTD return | -15.45% | -7.05% |
| 1-year return | -11.66% | +61.07% |
| 5-year return | -85.21% | — |
| P/E ratio (TTM) | 10.44 | — |
| Forward P/E | 9.15 | — |
| EPS (TTM) | $1.19 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $370.50M | $3.57M |
| Revenue growth (YoY) | -6.16% | +32.89% |
| Net income (latest FY) | $93.83M | $-7.80M |
| Gross margin | 78.54% | 84.23% |
| Operating margin | 23.05% | -219.37% |
| Net margin | 25.33% | -218.55% |
| 52-week high | $16.67 | $9.33 |
| 52-week low | $12.40 | $2.50 |
| Distance from 52-week high | -25.49% | -54.77% |
| Analyst consensus | hold | none |
| Avg. price target upside | +18.12% | +160.66% |
| Average volume | 529.24K | 148.58K |
| Shares outstanding | 57.54M | 14.19M |
| Employees | 660 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- InMode is about 11.9 times larger than Neuraxis by market value ($714.70M vs $59.90M).
- NRXS has outperformed INMD by 72.7 percentage points over the past year.
- InMode is more profitable, keeping 25.3 cents of every revenue dollar as net income versus -218.5 cents for Neuraxis.
- Neuraxis grew revenue faster in its latest fiscal year (+32.89% vs -6.16%).
About InMode
INMD stock →InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 660 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
INMD vs NRXS FAQ
Which is bigger, InMode or Neuraxis?
InMode (INMD) is larger, with a market capitalization of $714.70M compared with $59.90M for Neuraxis (NRXS).
Which stock has performed better over the past year, INMD or NRXS?
NRXS returned +61.07% over the past 12 months, compared with -11.66% for INMD (price return, excluding dividends). Past performance does not predict future results.
Are InMode and Neuraxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.